

1 **Title:**

2 Low daytime light and bright night-time light are associated with psychiatric disorders: an  
3 objective light study in >85,000 UK Biobank participants

4 **Proposed Author List:**

5 Angus C. Burns<sup>1,2,3</sup>, Daniel P. Windred<sup>1</sup>, Martin K. Rutter<sup>4,5</sup>, Patrick Olivier<sup>6</sup>, Céline Vetter<sup>7</sup>,  
6 Richa Saxena<sup>2,3,8</sup>, Jacqueline M. Lane<sup>2,3,9</sup>, Andrew J. K. Phillips<sup>1\*</sup>, Sean W. Cain<sup>1\*</sup>

7 **Affiliations:**

8 <sup>1</sup>Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash  
9 University, Melbourne, VIC, Australia;

10 <sup>2</sup>Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA;

11 <sup>3</sup>Broad Institute, Cambridge, MA, USA;

12 <sup>4</sup>Division of Endocrinology, Diabetes & Gastroenterology, School of Medical Sciences,  
13 Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.;

14 <sup>5</sup>Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation  
15 Trust, Manchester Academic Health Science Centre, Manchester, UK.;

16 <sup>6</sup>Action Lab, Faculty of Information Technology, Monash University, Clayton, VIC,  
17 Australia.

18 <sup>7</sup>Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, USA;

19 <sup>8</sup>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital  
20 and Harvard Medical School, Boston, MA, 02114, USA;

21 <sup>9</sup>Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA,  
22 02115, USA

23 \*Equal contribution

24 **Corresponding Authors:**

25 Angus C. Burns ([angus.burns1@monash.edu](mailto:angus.burns1@monash.edu)), Sean W. Cain ([sean.cain@monash.edu](mailto:sean.cain@monash.edu))  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

44 **Abstract.**

45

46 Circadian rhythm disturbance is a common feature of psychiatric disorders. Light is the  
47 primary input to the circadian clock, with daytime light exposure strengthening rhythms and  
48 nighttime light exposure weakening rhythms. However, the independent effects of day and  
49 night light exposure on psychiatric outcomes have not been well characterized. In this study,  
50 we performed the largest to-date cross-sectional analysis of objectively measured day and  
51 night light exposure and examined their relationship with psychiatric disorders. UK Biobank  
52 cohort participants aged 37-73 years were recruited into the UK Biobank general cohort  
53 population. In a subset of participants (n=86,772; 43% male), light and physical activity  
54 patterns were monitored for ~7 days. Using regression models adjusted for age, sex, ethnicity,  
55 photoperiod (day length), employment, and physical activity, we examined the independent  
56 associations of day and night-time light with psychiatric disorders and measures of symptom  
57 severity. We found that greater night light exposure was associated with greater odds of  
58 major depressive disorder (MDD), generalized anxiety disorder (GAD), bipolar disorder,  
59 post-traumatic stress disorder (PTSD), self-harm behavior and psychotic experiences.  
60 Conversely, greater daytime light exposure was associated with lower odds of MDD, PTSD,  
61 self-harm behavior and psychotic experiences. There was no significant association of day  
62 light exposure with GAD or bipolar disorder. Our findings demonstrate that low day light and  
63 bright night light exposure are associated with a wide range of psychiatric outcomes.  
64 Avoiding light at night and seeking light during the day may be a simple and effective, non-  
65 pharmacological means of broadly improving mental health.

66

67 *Funding*

68 Funded in part by the Australian Government Research Training Program and National  
69 Health and Medical Research Council (NHMRC; project number = GNT1183472).

70

71

72

73

74

75

76

77

78

79

80

81

82

## 83 Introduction.

84

85 Virtually all psychiatric disorders have been associated with disrupted circadian rhythms and  
86 sleep<sup>1</sup>. In humans, nearly every cell in the body contains a circadian (~24-hour) clock. These  
87 clocks regulate basic cellular functions, including gene expression for >80% of the protein  
88 coding genome<sup>2</sup>. The network of circadian clocks throughout the body is organized by a  
89 central ('master') circadian clock in the suprachiasmatic nucleus (SCN) in the hypothalamus.  
90 Rhythms within the SCN are regulated by daily light exposure patterns, with direct retinal  
91 inputs communicating light/dark information to the central circadian clock. This biological  
92 system evolved under predictable conditions of bright light during the day and very dim light  
93 during the night to ensure stable, robust rhythms<sup>3</sup>. Alterations to this pattern in daily life  
94 could contribute to adverse psychiatric outcomes.

95

96 In this study, we used objective recordings of daily light exposure data to characterize the  
97 levels of light in the day and night in a sample of 86,772 UK Biobank participants. We used  
98 these data to test the two primary hypotheses: (i) greater light exposure in the day is  
99 associated with better psychiatric outcomes and that (ii) greater light exposure at night is  
100 associated with worse psychiatric outcomes. These hypotheses were motivated by the known  
101 effects of day and night light exposure on the human circadian system, and the well-  
102 established links between circadian disruption and psychiatric disorders. Since the circadian  
103 system is implicated in regulating virtually all areas of physiology and behavior, we  
104 investigated a constellation of psychiatric outcomes available in the UK Biobank Mental  
105 Health Questionnaire.

106

## 107 Results.

108

109 Of the 103,669 UK Biobank participants that completed the actigraphy assessment, we  
110 excluded those with poor quality or unreliable accelerometry, sleep, and light data (see  
111 Methods for details), leaving 86,772 participants. Of these, 86,631 had complete data for day  
112 and night light as well as the covariates in our fully adjusted model 3. Light in the day and  
113 night showed extreme positive skew (skewness > 1 for both). As such, the day and night light  
114 variables were divided into four equally sized quartiles ( $n_{Q1-Q4} = 21,693$ ) in ascending  
115 brightness and were entered together as independent categorical predictors in all models  
116 (referent = Quartile 1, lowest brightness). Characteristics of the sample are presented in Table  
117 1 for the lowest (Q1 & Q2) and highest (Q3 & Q4) quartiles for both day and night light  
118 exposure.

119

120 The reliability of light measurements was assessed in a subset of the actigraphy sample ( $n =$   
121 2,988) that completed a series of four repeated actigraphy assessments. These assessments  
122 occurred on average 3.23 years (SD 0.65) after their initial assessment over the course of a  
123 year with three months between each measurement. A linear mixed-effects model with a  
124 crossed random effect structure including participant, assessment, and time of day was used  
125 to estimate the intra-class correlation (ICC) of light. Light measurements showed good  
126 reliability, ICC = 0.803.

127

128 339,092 UK Biobank participants were invited to complete the online Mental Health  
129 Questionnaire (MHQ) in 2016 and 157,366 completed the questionnaire. Measurement of  
130 psychiatric outcomes as part of the MHQ took place an average of 1.86 years (SD = 0.66)  
131 after the actigraphy assessment. The study sample comprised participants who completed  
132 both the MHQ and actigraphy assessment and sample sizes varied depending on the outcome

133 variable assessed, ranging from 26,956 to 61,442 for model 1 and 26,824 to 61,147 in model  
134 3.

135  
136 Figure 1 shows that in fully adjusted regression models (Model 3; adjusting for age, sex,  
137 ethnicity, photoperiod, physical activity and employment; see Table 2), when compared to  
138 participants in the lowest quartile of night light exposure (Q1), higher night light exposure  
139 was associated with higher odds of lifetime major depressive disorder (Likelihood Ratio Test  
140 (LRT)  $p < 0.0001$ ;  $OR_{Q4} = 1.30$ , 95% CI = 1.23-1.38,  $p < 0.0001$ ), self-harm (LRT  $p <$   
141  $0.0001$ ;  $OR_{Q4} = 1.27$ , 95% CI = 1.14-1.42,  $p < 0.0001$ ), generalized anxiety disorder (LRT  $p$   
142 = 0.0001;  $OR_{Q4} = 1.23$ , 95% CI = 1.11-1.36,  $p = 0.0001$ ), PTSD (LRT  $p < 0.0001$ ;  $OR_{Q4} =$   
143  $1.34$ , 95% CI = 1.22-1.48,  $p < 0.0001$ ), and lifetime psychotic experiences (LRT  $p = 0.0009$ ;  
144  $OR_{Q4} = 1.21$ , 95% CI = 1.09-1.34,  $p = 0.0003$ ). There was no overall association of night  
145 light exposure with lifetime bipolar disorder (LRT  $p = 0.18$ ), however, the brightest night  
146 light quartile was associated with increased odds of bipolar disorder ( $OR_{Q4} = 1.20$ , 95% CI =  
147  $1.02$ - $1.42$ ,  $p = 0.03$ ). Figure 2 shows that greater night light exposure was associated with  
148 higher scores on the PHQ-9 (LRT  $p < 0.0001$ ; Standardized  $\beta_{Q4} = 0.13$ , 95% CI = 0.11-0.15,  
149  $p < 0.0001$ ), GAD-7 (LRT  $p < 0.0001$ ;  $\beta_{Q4} = 0.07$ , 95% CI = 0.05-0.09,  $p < 0.0001$ ), PCL-6  
150 (LRT  $p < 0.0001$ ;  $\beta_{Q4} = 0.11$ , 95% CI = 0.08-0.14,  $p < 0.0001$ ) and lower wellbeing scores  
151 (LRT  $p < 0.0001$ ;  $\beta_{Q4} = -0.11$ , 95% CI = -0.13-0.08,  $p < 0.0001$ ; see Supplementary Table 1).  
152 The results for Model 1 (unadjusted) and Model 2 (adjusted for age, sex, ethnicity and  
153 photoperiod) were similar in terms of direction, strength and significance to Model 3.

154  
155 Figure 1 shows that in the fully adjusted regression models, higher day light exposure (see  
156 Table 3) was associated with lower odds of lifetime major depressive disorder (LRT  $p <$   
157  $0.0001$ ;  $OR_{Q4} = 0.81$ , 95% CI = 0.76-0.87,  $p < 0.0001$ ), self-harm (LRT  $p = 0.0001$ ;  $OR_{Q4} =$   
158  $0.76$ , 95% CI = 0.67-0.87,  $p = 0.0001$ ), PTSD (LRT  $p = 0.01$ ;  $OR_{Q4} = 0.82$ , 95% CI = 0.73-  
159  $0.92$ ,  $p = 0.001$ ) and psychotic experiences (LRT  $p < 0.0001$ ;  $OR_{Q4} = 0.69$ , 95% CI = 0.61-  
160  $0.79$ ,  $p < 0.0001$ ). There was no association of day light exposure with generalized anxiety  
161 disorder (LRT  $p = 0.61$ ;  $OR_{Q4} = 0.96$ , 95% CI = 0.85-1.09,  $p = 0.22$ ) or lifetime bipolar  
162 disorder (LRT  $p = 0.22$ ;  $OR_{Q4} = 0.86$ , 95% CI = 0.70-1.05,  $p = 0.13$ ). Figure 2 shows that  
163 greater day light exposure was associated with lower scores on the PHQ-9 (LRT  $p < 0.0001$ ;  
164  $\beta_{Q4} = -0.09$ , 95% CI = -0.12--0.07,  $p < 0.0001$ ), GAD-7 (LRT  $p < 0.0001$ ;  $\beta_{Q4} = -0.05$ , 95%  
165 CI = -0.08--0.03,  $p = 0.0001$ ), PCL-6 (LRT  $p = 0.002$ ;  $\beta_{Q4} = -0.08$ , 95% CI = -0.12-0.04,  $p =$   
166  $0.0001$ ) and higher wellbeing scores (LRT  $p < 0.0001$ ;  $\beta_{Q4} = 0.08$ , 95% CI = 0.05-0.11,  $p <$   
167  $0.0001$ ; see Supplementary Table 2). The results for Model 1 (unadjusted) and Model 2  
168 (adjusted for age, sex, ethnicity, and photoperiod) were similar in terms of direction and  
169 significance to Model 3. However, ORs tended to be smaller in Model 3 after the addition of  
170 physical activity and employment covariates.

## 171 172 **Discussion.**

173  
174 We found that objective light exposure patterns were associated with the likelihood of  
175 psychiatric disorders and the severity of symptoms across a broad range of outcomes.  
176 Brighter light at night was associated with a greater likelihood of depression, self-harm  
177 behavior, PTSD, psychosis, generalized anxiety disorder, and mania/hypomania. Brighter  
178 light in the day was associated with lower odds of depression, self-harm behavior, PTSD, and  
179 psychosis. These associations were independent of demographic, physical activity,  
180 photoperiod, and employment covariates.

181

182 The most striking results were observed for the influence of light at night on depression. For  
183 individuals in the brightest night light quartile, we saw ~30% higher risk of Major Depressive  
184 Disorder. Similar results were observed for self-harm behavior, Generalized Anxiety  
185 Disorder, and mood measured with the PHQ-9. Depression has long been associated with the  
186 disruption of both the timing and amplitude of circadian rhythms. Patients with depression  
187 have been found to have weakened circadian rhythms (blunted amplitude)<sup>4</sup> an effect that is  
188 reversed in recovery<sup>5,6</sup>. Greater disruption of circadian timing has been associated with  
189 poorer mood outcomes<sup>7,8</sup>. The severity of mood symptoms and the duration of depressive  
190 episodes are greater in those who experience circadian rhythm disturbance<sup>8,9</sup> and the presence  
191 of circadian disturbance in depression is predictive of a greater risk for recurrence<sup>10,11</sup>. In  
192 postmortem brain tissue from patients with MDD, a profound disruption in rhythms was seen  
193 throughout the brain<sup>12</sup>. As light at night alters circadian timing and dampens circadian  
194 amplitude<sup>13</sup>, our results are consistent with night light exposure as a cause of the disruption  
195 observed in people with depression. The human circadian system is highly sensitive to light  
196 at night<sup>14</sup>, but this sensitivity is profoundly enhanced by the common antidepressant  
197 citalopram<sup>15</sup>. Thus, treatment of depression with these drugs could play a causal role in  
198 exacerbating circadian disruption. Patients with depression who tend to get more light at  
199 night responded more poorly to SSRIs, switching medications more often and having more  
200 suicidal ideation<sup>16</sup>. Together, these findings point to the avoidance of light at night as an  
201 important therapeutic target for recovery.

202  
203 We found that brighter light in the day was associated with ~20% lower odds of Major  
204 Depressive Disorder, less self-harm behavior, and better mood on the PHQ-9. Daytime light  
205 therapy has long been shown to be efficacious in treating both seasonal and non-seasonal  
206 depression<sup>17</sup>. Light therapy has also been shown to significantly enhance treatment efficacy  
207 with a selective serotonin reuptake inhibitor<sup>18</sup>. Our findings suggest that the use of  
208 specialized light therapy boxes are not necessary for therapeutic effects of light. Our findings  
209 of objective measurements of daytime light exposure are consistent with our previous finding  
210 of an association of self-reported outdoor light exposure in >400,000 participants<sup>19</sup>. In that  
211 study, self-reported greater time spent outdoors during the day was associated with lower  
212 odds of lifetime major depressive disorder, less antidepressant usage, less frequent anhedonia,  
213 greater happiness, and lower neuroticism. Those findings were independent of demographic,  
214 lifestyle, and employment covariates and held in both cross-sectional and longitudinal  
215 analyses. Thus, both large-scale objective and subjective light exposure data demonstrate the  
216 beneficial effect of daytime light exposure on depression. Getting more light exposure in the  
217 day, and not necessarily in the morning, could be a simple means of improving depression  
218 trajectories.

219  
220 At high levels of light exposure at night, we observed higher odds of bipolar disorder. Similar  
221 to depression, bipolar disorder has long been associated with circadian disruption (for a  
222 review, see<sup>20</sup>). In bipolar disorder, there is greater variability of circadian timing and a  
223 dampened amplitude of behavioral rhythms, both of which could be indicative of circadian  
224 disruption by light at night. Hypersensitivity of the circadian system to light at night has been  
225 proposed to be a trait marker of bipolar disorder<sup>21,22</sup>. Drugs used to treat bipolar disorder have  
226 been shown to reduce the sensitivity of the circadian system to light at night<sup>23,24</sup> suggesting  
227 that a normalization of circadian light sensitivity may play a role in recovery by reducing the  
228 effects of light at night. Increased sensitivity to light may occur at the level of the retinal  
229 circadian photoreceptors (intrinsically photosensitive retinal ganglion cells; ipRGCs) that are  
230 highly sensitive to short-wavelength (“blue”) light<sup>25</sup> as trait hypomania has been shown to be  
231 associated with increased ipRGC responsiveness to blue light<sup>26</sup>. Consistent with this, wearing

232 blue-blocking glasses at night was found to be effective in reducing mania in patients<sup>27</sup>. We  
233 did not see significant associations of bipolar disorder or hypomania/mania with brighter  
234 daytime light. This may reflect a ceiling effect of any light in the day on an already highly  
235 sensitive circadian system. For patients with episodes of mania, the avoidance of light at  
236 night specifically may be beneficial.

237  
238 We found both an adverse association of nighttime light exposure and a beneficial association  
239 of daytime light exposure with PTSD. In previous studies, circadian dysrhythmia has been  
240 associated with symptom severity in PTSD<sup>28</sup> and lower urinary melatonin levels after a  
241 trauma exposure have been found to predict a higher risk for PTSD<sup>29</sup>, a finding replicated in  
242 military personnel<sup>30</sup>. Though it is possible that low endogenous melatonin levels may  
243 produce this increased PTSD vulnerability, our results suggest bright night light exposure  
244 and/or high circadian light sensitivity may be antecedent factors leading to blunted and  
245 disrupted rhythms. This is supported by evidence that melatonin and phase advancing  
246 daytime light may be effective treatments for PTSD symptoms<sup>31,32</sup>. Furthermore, we have  
247 recently demonstrated that PTSD is genetically correlated with greater light sensitivity<sup>33</sup>. The  
248 avoidance of light at night and seeking bright daytime light after trauma may reduce the  
249 likelihood of developing PTSD and the severity of symptoms in those with the disorder.

250  
251 Taken together, our findings of associations of brighter light in the day and less light at night  
252 as generally beneficial for psychiatric health point to the strengthening of circadian rhythms  
253 as an underlying factor supporting more robust mental health. Patterns of bright daytime light  
254 and low nighttime light can enhance the amplitude of the circadian clock strengthening the  
255 clock's control of circadian rhythms throughout the brain and body. High amplitude rhythms  
256 are also protective against perturbations from the disruptive effects of light at night. As  
257 modern humans spend ~90% of the day indoors<sup>34</sup>, our light exposure patterns are typically  
258 less bright in the day and more bright at night than naturalistic patterns across our  
259 evolutionary history<sup>35</sup>. These patterns of low daytime light and bright light at night dampen  
260 the amplitude of circadian rhythms generated within the core circadian clock, leading to  
261 downstream disorganization of rhythms throughout the brain and body. Targeting circadian  
262 health is a highly promising means of promoting optimal general physiology, leading to more  
263 robust mental and general health.

264  
265 Though light at night can induce poor mood in the long term via circadian disruption (like a  
266 perpetual jet lag), in the short term, light may be sought to acutely benefit mood. Light can  
267 enhance mood acutely. We have recently shown that light can acutely inhibit activity of the  
268 amygdala in humans<sup>36</sup> (a brain region involved in negative emotionality), with brighter light  
269 resulting in more suppression of amygdala activity. That study also showed that light dose-  
270 dependently enhanced the connectivity between the ventro-medial prefrontal cortex and  
271 amygdala, suggesting that light can enhance the control of negative emotionality. As poor  
272 mood is generally higher in the night/early morning hours<sup>37</sup>, those experiencing such  
273 challenges may seek light at these times to enhance mood. Though this would enhance mood  
274 in the short term, it would lead to circadian disruption in the long term and potentially act to  
275 perpetuate mental illness. Such motivations toward light represent a potential challenge for  
276 promoting healthy light behaviors. However, these motivations to seek light may make the  
277 monitoring of self-exposure to light at night using wearables<sup>38,39</sup> a promising means of  
278 tracking mood in patients.

279  
280 This study is the first to report an analysis of objectively measured light exposure data from  
281 the UK Biobank and is the largest examination of objective light exposure and mental health

282 to date. Across a broad range of psychiatric outcomes, our results demonstrate a powerful  
283 impact of healthy light exposure patterns. These results suggest that promoting brighter days  
284 and darker nights as a simple, freely available non-pharmacological intervention to enhance  
285 mental health.

286

## 287 **Methods.**

288

### 289 **Participants.**

290

291 The UK Biobank prospective general population cohort contains more than 502,000 UK  
292 residents (aged 37–73 years; ~54% women) recruited via National Health Service (NHS)  
293 patient registers from 2006 to 2010. The study population is described in detail elsewhere<sup>40,41</sup>.  
294 Participants provided detailed demographic, lifestyle, health, and employment information  
295 via assessment and touch-screen questionnaire. Accelerometry and light data were measured  
296 in a subset of more than 100,000 participants in 2013-2015 and approximately 160,000  
297 participants completed an online Mental Health Questionnaire (MHQ) in 2016-2017. Our  
298 sample comprised participants whose activity and light data measurements passed rigorous  
299 quality control and had data on all covariates across regression models of increasing  
300 adjustment. Characteristics of participants with low (quartiles 1 & 2) and high (quartiles 3 &  
301 4) day and night light exposure groups are presented in Table 1. Participants who accepted  
302 the invitation to join the UK Biobank cohort provided written, informed consent and the UK  
303 Biobank has generic ethical approval from the North West Multi-Center Research Ethics  
304 Committee (ref 11/NW/03820).

305

### 306 **Measurement of predictors**

307

308 In 2013, 240,000 UK Biobank participants were invited to wear an accelerometer for 7 days  
309 as part of a physical activity and light monitoring study. Of these participants, 103,669 (43%)  
310 accepted, and returned the accelerometer to UK Biobank after use. Participants who accepted  
311 the invitation received a wrist-worn AX3 triaxial accelerometer (Axivity, Newcastle upon  
312 Tyne, UK) with in-built light sensor (APDS9007 silicon photodiode sensor; spectral  
313 sensitivity  $\lambda = 470\text{-}650\text{nm}$ ) in the post and were asked to wear the device on their dominant  
314 wrist continuously for 7 days, while continuing with their normal activities. At the end of the  
315 7-day period, participants were instructed to return the accelerometer to UK Biobank using a  
316 prepaid envelope.

317

318 Output current of the light sensor was extracted from the Axivity CWA files, down-sampled  
319 from 100Hz to 1Hz and converted from the logarithmic scale to approximate lux according to  
320 the device manual ( $\text{lux} = 10^{(\text{device output current}/341)}$ ). Initial pre-processing of the light  
321 data involved averaging 1Hz light samples into 10-second epochs. Participants' light data  
322 were then cleaned based on accelerometer non-wear. Non-wear was defined by GGIR  
323 according to previously validated methodology<sup>42,43</sup>. Participants without valid days of sleep-  
324 wake data due to file corruption or consistent non-wear were also excluded. Of the 103,669  
325 participants, 8,004 were excluded. The median (IQR) number of days of light data excluded  
326 in this process per participant was 0.06 (0.00-0.01) and the median (IQR) number of valid  
327 days per participant was 6.90 (5.95-6.99). Epochs were then smoothed with a median rolling  
328 window (10-minute window, 2-minute increments). Participants were then excluded if they  
329 had unusually dark (percentage of data below 1lux > 80%), consistently bright (percentage of  
330 data above 600lux >75%) or irregular light patterns (LRI > 100 or < 0) leaving 88,014  
331 participants remaining.

332

333 Daily light profiles of participants were constructed by averaging epochs into forty-eight 30-  
334 min bins across the 24-hour period per study day and these bins were then averaged across  
335 the study days to generate an average 24-hour light exposure profile per-participant (i.e. a  
336 single 30-minute bin contained the average light exposure across the seven study days).  
337 Participants with < 2 study days' worth of light data per 30-minute bin were excluded,  
338 resulting in the loss of 18,301 bins of a possible 4,268,016 (0.43%) and 1,242 participants for  
339 a final sample of 86,772.

340

341 Light exposure predictors were defined by factor analysis of the forty-eight 30-minute light  
342 bins across the 24-hour period to identify superordinate patterns in light exposure behavior in  
343 the sample. Factor analysis supported the extraction of a two-factor structure (day, 7.30am-  
344 8.30pm; and night, 12.30am-6am; factor loadings  $\geq 0.5$ , varimax rotation) based on the scree  
345 plot, the additional proportion of variance explained by each factor ( $>0.1$ ) and the  
346 independence of resultant factors. A three-factor structure including an evening (7.30pm-  
347 12.00am) factor was also explored, however, day and evening light were strongly correlated  
348 ( $r = 0.76$ ), indicating they were not independent and likely to misbehave in regression  
349 models, and evening light bins had considerable cross-loading onto the day factor. As such,  
350 the two-factor model was retained (cumulative proportion of variance explained = 0.56). Day  
351 and night light variables were calculated by averaging light values across the respective time  
352 bins.

353

354 Light exposure during the day had a small positive correlation with night light ( $r = 0.08$ ,  $p <$   
355  $0.0001$ ). Internal consistency of both day (Cronbach's  $\alpha = 0.98$ ) and night ( $\alpha = 0.93$ ) light  
356 variables was very good. Test-retest reliability of day and night light measurements was  
357 assessed in a subset of the actigraphy sample ( $n = 2,988$ ) that completed a series of four  
358 repeated actigraphy assessments. These repeated assessments occurred on average 3.23 years  
359 ( $SD = 0.65$ ) after the main assessment and took place over the course of a year with three  
360 months between each measurement. A linear mixed-effects model with a crossed random  
361 effect structure including participant, assessment, and time of day was used to estimate the  
362 intra-class correlation (ICC). Light measurements showed good reliability,  $ICC = 0.803$ .

363

### 364 **Measurement of outcomes**

365

366 Definition of case-control psychiatric outcome variables from the UK Biobank MHQ  
367 followed guidelines established by Davis, Coleman<sup>44</sup>. Lifetime major depressive disorder  
368 cases were defined according to the CIDI-SF lifetime depression module based on the DSM  
369 definition of major depressive disorder<sup>45</sup>. Cases were those who reported that they had at  
370 least one core symptom of depression (persistent sadness or loss of interest), most or all of  
371 the day on most or all days for a two-week period, with at least five depressive symptoms that  
372 represent a change from usual occurring over the same time scale with some or a lot of  
373 impairment. Individuals who reported a depression diagnosis were also recorded as cases  
374 (UKB 20544 & 20002). Controls were those who did not meet the above criteria and did not  
375 report either of the canonical symptoms or a PHQ-9 score  $> 5$ . Lifetime generalized anxiety  
376 disorder cases according to the CIDI-SF lifetime GAD module based on the DSM-IV  
377 definition of GAD<sup>45</sup>. Cases were those who reported excessive worrying about a number of  
378 issues, occurring most days for six months and that were difficult to control, with three or  
379 more somatic symptoms and functional impairment. Lifetime bipolar disorder cases were  
380 defined according to DSM-IV guidelines<sup>46,47</sup>. Cases were those who reported that they were  
381 ever manic/hyper or irritable plus four other features of bipolar disorder for a duration of a



382 week or more with the symptoms causing significant problems or those who self-reported a  
383 diagnosis of bipolar or mania (20544 = 10). Self-harm cases and controls were defined by yes  
384 or no responses to the question “have you ever deliberately harmed yourself, whether or not  
385 you meant to end your life?”. PTSD was defined using the PTSD-Checklist-6 using a clinical  
386 case-control threshold of 13<sup>48</sup>. Lifetime psychotic experiences cases were defined using  
387 participant responses to the MHQ which were adapted from the CIDI<sup>49</sup>. Cases were those  
388 who reported hearing an unreal voice, seeing an unreal vision, believing an unreal conspiracy,  
389 believing an unreal communication or sign or had a diagnosis of schizophrenia or psychotic  
390 illness (20544 = 2 or 3). Controls were those who did not meet the above criteria.

391  
392 Continuous symptom severity scales for depression (PHQ-9; range = 0-27), anxiety (GAD-7,  
393 range = 0-21) and PTSD (PCL-6, range = 6-29) were calculated by summing across the  
394 individual items in the MHQ to generate a total score<sup>48,50</sup>. A total well-being score was  
395 calculated by summing across three items indexing general happiness (20458), happiness  
396 with health (20459) and life meaningfulness (20460; range 3-17).

### 397 398 **Statistical analysis**

399  
400 Associations between day and night light exposure and each of the psychiatric outcome  
401 variables were examined in three separate regression models with increasing adjustment for  
402 potential confounders. Each model included both day and night light categorical predictors to  
403 examine their independent effects.

404  
405 Due to the large positive skew in both day and night light variables (skewness > 1 for both)  
406 and zero-inflation of the night light variable, both variables were converted into categorical  
407 predictors by dividing them into four equal-sized quartiles ( $n_{Q1-Q4} = 21,693$ ) in ascending  
408 brightness. Four bins were chosen to maximize the per-bin sample size while allowing for the  
409 observation of non-linear effects.

410  
411 The association between day and night light and case/control outcomes of lifetime major  
412 depressive disorder, self-harm, GAD, PTSD, bipolar disorder, and psychotic experiences  
413 were examined with multiple logistic regression. Odds ratios (OR) and their 95% confidence  
414 intervals are reported. Linear regression was used for all continuous symptom severity scales  
415 and standardized beta values are reported. For all models, a likelihood-ratio test was used as  
416 an omnibus test of significance for the day and night light factors by comparing a model with  
417 the given light variable included against a model without it. These associations were tested  
418 hierarchically in three models with increasing adjustment for potential confounders. Model 1  
419 examined the unadjusted association between day and night light and psychiatric outcomes.  
420 Model 2 adjusted for age at the time of actigraphy, sex, ethnicity (white vs. non-white),  
421 photoperiod as a measure of seasonality defined as the duration between sunrise and sunset at  
422 the beginning of the actigraphy assessment. Finally, model 3 additionally adjusted for  
423 employment (employed vs. unemployed) and physical activity defined as overall acceleration  
424 average in milligravity units (UKB field 90012). Data preprocessing for the physical activity  
425 measure was done by the UK Biobank accelerometer expert working group<sup>42</sup>. Coefficient  
426 plots of the three models were constructed with inside and outside error bars reflecting one  
427 standard error of the mean and the 95% confidence interval, respectively.

### 428 429 **Role of the funding source**

430

431 The funder of the study played no role in study design, data collection, data analysis, data  
432 interpretation or writing of the report. The corresponding authors have full access to the study  
433 data and final responsibility for the decision to submit for publication.

434

#### 435 **Conflicts of interest**

436

437 AJKP and SWC have received research funding from Delos and Versalux, and they are co-  
438 founders and co-directors of Circadian Health Innovations PTY LTD. SWC has also received  
439 research funding from Beacon Lighting and has consulted for Dyson. ACB: none; DPW:  
440 none; MKR: none; RS: none; JML: none; CV: none; PO: none.

441

#### 442 **Data availability statement**

443

444 This work utilized the UK Biobank resource (application 26209; Martin Rutter).

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481 **References.**

482

483 1. Freeman D, Sheaves B, Waite F, Harvey AG, Harrison PJ. Sleep disturbance and  
484 psychiatric disorders. *The Lancet Psychiatry* 2020; **7**(7): 628-37.

485 2. Mure LS, Le HD, Benegiamo G, et al. Diurnal transcriptome atlas of a primate across  
486 major neural and peripheral tissues. *Science* 2018; **359**(6381).

487 3. Winfree AT. *The Geometry of Biological Time*: Springer New York; 1980.

488 4. Sou  tre E, Salvati E, Belugou JL, et al. Circadian rhythms in depression and  
489 recovery: evidence for blunted amplitude as the main chronobiological abnormality.  
490 *Psychiatry research* 1989; **28**: 263-78.

491 5. Avery DH, Wildschiodtz G, Rafaelsen OJ. Nocturnal temperature in affective  
492 disorder. *J Affect Disord* 1982; **4**(1): 61-71.

493 6. Szuba MP, Guze BH, Baxter LR, Jr. Electroconvulsive therapy increases circadian  
494 amplitude and lowers core body temperature in depressed subjects. *Biological psychiatry*  
495 1997; **42**(12): 1130-7.

496 7. Coleman MY, McGlashan EM, Vidafar P, Phillips AJK, Cain SW. Advanced  
497 melatonin onset relative to sleep in women with unmedicated major depressive disorder.  
498 *Chronobiol Int* 2019; **36**(10): 1373-83.

499 8. Emens J, Lewy A, Kinzie JM, Arntz D, Rough J. Circadian misalignment in major  
500 depressive disorder. *Psychiatry Res* 2009; **168**(3): 259-61.

501 9. Hasler BP, Buysse DJ, Kupfer DJ, Germain A. Phase relationships between core  
502 body temperature, melatonin, and sleep are associated with depression severity: further  
503 evidence for circadian misalignment in non-seasonal depression. *Psychiatry Res* 2010;  
504 **178**(1): 205-7.

505 10. Harvey A. Sleep and circadian functioning: critical mechanisms in the mood  
506 disorders? *Annual review of clinical psychology* 2011; **7**: 297-319.

507 11. Monteleone P, Maj M. The circadian basis of mood disorders: recent developments  
508 and treatment implications. *European neuropsychopharmacology : the journal of the*  
509 *European College of Neuropsychopharmacology* 2008; **18**: 701-11.

510 12. Li JZ, Bunney BG, Meng F, et al. Circadian patterns of gene expression in the human  
511 brain and disruption in major depressive disorder. *Proceedings of the National Academy of*  
512 *Sciences of the United States of America* 2013; **110**(24): 9950-5.

513 13. Jewett ME, Kronauer RE, Czeisler CA. Phase-amplitude resetting of the human  
514 circadian pacemaker via bright light: a further analysis. *J Biol Rhythms* 1994; **9**(3-4): 295-  
515 314.

516 14. Phillips AJK, Vidafar P, Burns AC, et al. High sensitivity and interindividual variability  
517 in the response of the human circadian system to evening light. *Proc Natl Acad Sci U S A*  
518 2019; **116**(24): 12019-24.

519 15. McGlashan EM, Nandam LS, Vidafar P, Mansfield DR, Rajaratnam SMW, Cain SW.  
520 The SSRI citalopram increases the sensitivity of the human circadian system to light in an  
521 acute dose. *Psychopharmacology (Berl)* 2018; **235**(11): 3201-9.

522 16. McGlashan EM, Drummond SPA, Cain SW. Evening types demonstrate reduced  
523 SSRI treatment efficacy. *Chronobiol Int* 2018; **35**(8): 1175-8.

524 17. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the  
525 treatment of mood disorders: a review and meta-analysis of the evidence. *Am J Psychiatry*  
526 2005; **162**(4): 656-62.


527 18. Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of Bright Light Treatment, Fluoxetine,  
528 and the Combination in Patients With Nonseasonal Major Depressive Disorder: A  
529 Randomized Clinical Trial. *JAMA Psychiatry* 2016; **73**(1): 56-63.

530 19. Burns AC, Saxena R, Vetter C, Phillips AJK, Lane JM, Cain SW. Time spent in  
531 outdoor light is associated with mood, sleep, and circadian rhythm-related outcomes: A  
532 cross-sectional and longitudinal study in over 400,000 UK Biobank participants. *J Affect*  
533 *Disord* 2021; **295**: 347-52.

- 534 20. McCarthy MJ, Gottlieb JF, Gonzalez R, et al. Neurobiological and behavioral  
535 mechanisms of circadian rhythm disruption in bipolar disorder: A critical multi-disciplinary  
536 literature review and agenda for future research from the ISBD task force on chronobiology.  
537 *Bipolar disorders* 2022; **24**(3): 232-63.
- 538 21. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Rosenthal NE. Manic-depressive  
539 patients may be supersensitive to light. *Lancet (London, England)* 1981; **1**(8216): 383-4.
- 540 22. Lewy AJ, Nurnberger JI, Jr., Wehr TA, et al. Supersensitivity to light: possible trait  
541 marker for manic-depressive illness. *The American journal of psychiatry* 1985; **142**(6): 725-7.
- 542 23. Hallam KT, Olver JS, Horgan JE, McGrath C, Norman TR. Low doses of lithium  
543 carbonate reduce melatonin light sensitivity in healthy volunteers. *The international journal of*  
544 *neuropsychopharmacology* 2005; **8**(2): 255-9.
- 545 24. Hallam KT, Olver JS, Norman TR. Effect of sodium valproate on nocturnal melatonin  
546 sensitivity to light in healthy volunteers. *Neuropsychopharmacology* 2005; **30**(7): 1400-4.
- 547 25. Bailes HJ, Lucas RJ. Human melanopsin forms a pigment maximally sensitive to blue  
548 light (lambda<sub>max</sub> approximately 479 nm) supporting activation of G(q/11) and G(i/o)  
549 signalling cascades. *Proc Biol Sci* 2013; **280**(1759): 20122987.
- 550 26. Bullock B, McGlashan EM, Burns AC, Lu BS, Cain SW. Traits related to bipolar  
551 disorder are associated with an increased post-illumination pupil response. *Psychiatry Res*  
552 2019; **278**: 35-41.
- 553 27. Henriksen TE, Skrede S, Fasmer OB, et al. Blue-blocking glasses as additive  
554 treatment for mania: a randomized placebo-controlled trial. *Bipolar Disord* 2016; **18**(3): 221-  
555 32.
- 556 28. Sandahl H, Baandrup L, Vindbjerg E, Jennum P, Carlsson J. Social zeitgebers and  
557 circadian dysrhythmia are associated with severity of symptoms of PTSD and depression in  
558 trauma-affected refugees. *European Archives of Psychiatry and Clinical Neuroscience* 2021;  
559 **271**(7): 1319-29.
- 560 29. McFarlane AC, Barton CA, Briggs N, Kennaway DJ. The relationship between urinary  
561 melatonin metabolite excretion and posttraumatic symptoms following traumatic injury. *J*  
562 *Affect Disord* 2010; **127**(1-3): 365-9.
- 563 30. Paul MA, Love RJ, Jetly R, et al. Blunted Nocturnal Salivary Melatonin Secretion  
564 Profiles in Military-Related Posttraumatic Stress Disorder. *Frontiers in psychiatry* 2019; **10**:  
565 882.
- 566 31. Youngstedt SD, Kline CE, Reynolds AM, et al. Bright Light Treatment of Combat-  
567 related PTSD: A Randomized Controlled Trial. *Military Medicine* 2022; **187**(3-4): e435-e44.
- 568 32. Agorastos A, Linthorst AC. Potential pleiotropic beneficial effects of adjuvant  
569 melatonergic treatment in posttraumatic stress disorder. *Journal of pineal research* 2016;  
570 **61**(1): 3-26.
- 571 33. Burns AC, Phillips, A.J.K., Rutter, M.K., Saxena, R., Cain, S.W., Lane, J.M. Genome-  
572 wide gene by environment study of time spent in daylight and chronotype identifies emerging  
573 genetic architecture underlying light sensitivity. *medRxiv* 2022; **2022.06.29.22277078**.
- 574 34. Klepeis NE, Nelson WC, Ott WR, et al. The National Human Activity Pattern Survey  
575 (NHAPS): a resource for assessing exposure to environmental pollutants. *Journal of*  
576 *Exposure Science & Environmental Epidemiology* 2001; **11**(3): 231-52.
- 577 35. Wright KP, Jr., McHill AW, Birks BR, Griffin BR, Rusterholz T, Chinoy ED.  
578 Entrainment of the human circadian clock to the natural light-dark cycle. *Current biology : CB*  
579 2013; **23**(16): 1554-8.
- 580 36. McGlashan EM, Poudel GR, Jamadar SD, Phillips AJK, Cain SW. Afraid of the dark:  
581 Light acutely suppresses activity in the human amygdala. *PLoS One* 2021; **16**(6): e0252350.
- 582 37. Wirz-Justice A. Diurnal variation of depressive symptoms. *Dialogues Clin Neurosci*  
583 2008; **10**(3): 337-43.
- 584 38. Cain SW, McGlashan EM, Vidasfar P, et al. Evening home lighting adversely impacts  
585 the circadian system and sleep. *Sci Rep* 2020; **10**(1): 19110.
- 586 39. Mohamed A, Kalavally V, Cain SW, Phillips AJK, McGlashan EM, Tan CP. Wearable  
587 light spectral sensor optimized for measuring daily alpha-opic light exposure. *Opt Express*  
588 2021; **29**(17): 27612-27.


589 40. Collins R. What makes UK Biobank special? *The Lancet* 2012; **9822**(379): 1173-4.  
590 41. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for  
591 identifying the causes of a wide range of complex diseases of middle and old age. *PLOS*  
592 *Medicine* 2015; **12**(3): e1001779.  
593 42. Doherty A, Jackson D, Hammerla N, et al. Large Scale Population Assessment of  
594 Physical Activity Using Wrist Worn Accelerometers: The UK Biobank Study. *PLOS ONE*  
595 2017; **12**(2): e0169649.  
596 43. Windred DP, Jones SE, Russell A, et al. Objective assessment of sleep regularity in  
597 60 000 UK Biobank participants using an open-source package. *Sleep* 2021; **44**(12).  
598 44. Davis KAS, Coleman JRI, Adams M, et al. Mental health in UK Biobank -  
599 development, implementation and results from an online questionnaire completed by 157  
600 366 participants: a reanalysis. *BJPsych open* 2020; **6**(2): e18.  
601 45. Kessler RC, Andrews G, Mroczek D, Ustun B, Wittchen H-U. The World Health  
602 Organization Composite International Diagnostic Interview short-form (CIDI-SF).  
603 *International Journal of Methods in Psychiatric Research* 1998; **7**(4): 171-85.  
604 46. Carvalho AF, Takwoingi Y, Sales PMG, et al. Screening for bipolar spectrum  
605 disorders: A comprehensive meta-analysis of accuracy studies. *Journal of Affective*  
606 *Disorders* 2015; **172**: 337-46.  
607 47. Cerimele JM, Chwastiak LA, Dodson S, Katon WJ. The prevalence of bipolar  
608 disorder in general primary care samples: a systematic review. *General Hospital Psychiatry*  
609 2014; **36**(1): 19-25.  
610 48. Lang AJ, Stein MB. An abbreviated PTSD checklist for use as a screening instrument  
611 in primary care. *Behaviour Research and Therapy* 2005; **43**(5): 585-94.  
612 49. Nuevo R, Chatterji S, Verdes E, Naidoo N, Arango C, Ayuso-Mateos JL. The  
613 Continuum of Psychotic Symptoms in the General Population: A Cross-national Study.  
614 *Schizophrenia Bulletin* 2010; **38**(3): 475-85.  
615 50. Kroenke K, Spitzer RL, Williams JBW, Löwe B. The Patient Health Questionnaire  
616 Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. *General Hospital*  
617 *Psychiatry* 2010; **32**(4): 345-59.  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640

641 **Figures**  
642



643 **Figure 1.** Coefficients plot for day and night-time light associations with (A) major  
644 depressive disorder, (B) self-harm behavior, (C) generalized anxiety disorder, (D) PTSD, (E)  
645 bipolar disorder and (F) psychotic experiences. Coefficients represent the odds ratios  $\pm$  the  
646 SEM (inner error bar) and 95% CI (outer error bar) for each quartile of day and night light  
647 exposure relative to the low light (Q1) referent. Three models are presented with increasing  
648 adjustment for confounders: Model 1 (green) is unadjusted, Model 2 (blue) adjusts for age,  
649 sex, ethnicity and photoperiod and Model 3 (red) additionally adjusts for employment and  
650 physical activity.  
651  
652

653  
654  
655  
656  
657  
658



659  
 660  
 661  
 662  
 663  
 664  
 665  
 666  
 667  
 668  
 669  
 670  
 671  
 672  
 673  
 674  
 675  
 676  
 677  
 678  
 679  
 680  
 681  
 682  
 683

**Figure 2.** Coefficients plot for day and night-time light associations with (A) PHQ-9 score, (B) wellbeing score, (C) GAD-7 score and (D) PCL-6 score. Coefficients represent the standardized betas  $\pm$  the SEM (inner error bar) and 95% CI (outer error bar) for each quartile of day and night light exposure relative to the low light (Q1) referent. Three models are presented with increasing adjustment for confounders: Model 1 (green) is unadjusted, Model 2 (blue) adjusts for age, sex, ethnicity and photoperiod and Model 3 (red) additionally adjusts for employment and physical activity.

**Table 1.** Demographic characteristics of participants by low and high day and night light exposure

	Day light			Night light		
	Low Q1 & Q2 N=43386	High Q3 & Q4 N=43386	<i>p</i> value	Low Q1 & Q2 N=43387	High Q3 & Q4 N=43385	<i>p</i> value
<b>Age</b>						
Mean (SD)	62.0 (7.94)	62.7 (7.71)	<0.001	62.6 (7.86)	62.1 (7.79)	<0.001
Median [Min, Max]	62.9 [43.6, 78.9]	64.0 [43.5, 78.8]		63.8 [43.5, 78.8]	63.2 [43.5, 78.9]	
<b>Sex</b>						
Female	25159 (58.0%)	24321 (56.1%)	<0.001	25352 (58.4%)	24128 (55.6%)	<0.001
Male	18227 (42.0%)	19065 (43.9%)		18035 (41.6%)	19257 (44.4%)	
<b>BMI</b>						
Mean (SD)	26.7 (4.57)	26.7 (4.47)	0.212	26.3 (4.31)	27.1 (4.68)	<0.001
Median [Min, Max]	26.0 [12.1, 67.3]	26.1 [14.1, 65.2]		25.7 [14.7, 58.4]	26.4 [12.1, 67.3]	
Missing	102 (0.2%)	83 (0.2%)		83 (0.2%)	102 (0.2%)	
<b>White ethnicity</b>						
	41679 (96.1%)	42226 (97.3%)	<0.001	42233 (97.3%)	41672 (96.1%)	<0.001
Missing	150 (0.3%)	141 (0.3%)		136 (0.3%)	155 (0.4%)	
<b>Employment</b>						
No	15912 (36.7%)	17412 (40.1%)	<0.001	17353 (40.0%)	15971 (36.8%)	<0.001
Yes	27474 (63.3%)	25974 (59.9%)		26034 (60.0%)	27414 (63.2%)	
<b>Shiftwork</b>						
No	39780 (91.7%)	40152 (92.5%)	<0.001	40545 (93.4%)	39387 (90.8%)	<0.001
Yes	3606 (8.3%)	3234 (7.5%)		2842 (6.6%)	3998 (9.2%)	
<b>Townsend</b>						
Mean (SD)	-1.60 (2.89)	-1.94 (2.68)	<0.001	-1.93 (2.69)	-1.61 (2.87)	<0.001
Median [Min, Max]	-2.34 [-6.26, 10.5]	-2.60 [-6.26, 9.89]		-2.60 [-6.26, 10.5]	-2.35 [-6.26, 9.99]	
<b>Physical activity</b>						
Mean (SD)	27.3 (7.89)	29.0 (8.16)	<0.001	28.1 (7.97)	28.3 (8.17)	<0.001
Median [Min, Max]	26.4 [5.12, 69.3]	28.1 [4.83, 69.4]		27.1 [4.83, 69.2]	27.3 [5.12, 69.4]	
Missing	39 (0.1%)	94 (0.2%)		60 (0.1%)	73 (0.2%)	
<b>Photoperiod</b>						
Mean (SD)	10.9 (2.87)	14.1 (2.58)	<0.001	12.4 (3.06)	12.6 (3.28)	<0.001
Median [Min, Max]	10.2 [7.47, 17.0]	14.8 [7.47, 17.0]		12.4 [7.47, 17.0]	12.8 [7.47, 17.0]	



**Table 2.** Associations between night light exposure and psychiatric outcomes

Night light	Model 1 OR (95% CI)				Model 2 aOR (95% CI)*				Model 3 aOR (95% CI) <sup>†</sup>			
	2 <sup>nd</sup> Quartile	3 <sup>rd</sup> Quartile	4 <sup>th</sup> Quartile	LRT <i>p</i> <sup>‡</sup>	2 <sup>nd</sup> Quartile	3 <sup>rd</sup> Quartile	4 <sup>th</sup> Quartile	LRT <i>p</i> <sup>‡</sup>	2 <sup>nd</sup> Quartile	3 <sup>rd</sup> Quartile	4 <sup>th</sup> Quartile	LRT <i>p</i> <sup>‡</sup>
<b>Major depressive disorder</b>	1.05 (1.00 – 1.11)	<b>1.17</b> ( <b>1.11 – 1.24</b> )	<b>1.28</b> ( <b>1.22 – 1.36</b> )	< <b>0.0001</b>	1.04 (0.98 – 1.09)	<b>1.17</b> ( <b>1.11 – 1.24</b> )	<b>1.32</b> ( <b>1.25 – 1.39</b> )	< <b>0.0001</b>	1.04 (0.98 – 1.10)	<b>1.18</b> ( <b>1.12 – 1.25</b> )	<b>1.30</b> ( <b>1.23 – 1.38</b> )	< <b>0.0001</b>
<b>Self-harm</b>	1.02 (0.91 – 1.14)	1.03 (0.92 – 1.15)	<b>1.28</b> ( <b>1.15 – 1.42</b> )	< <b>0.0001</b>	0.99 (0.88 – 1.10)	0.99 (0.88 – 1.11)	<b>1.28</b> ( <b>1.15 – 1.43</b> )	< <b>0.0001</b>	0.99 (0.88 – 1.11)	1.00 (0.89 – 1.12)	<b>1.27</b> ( <b>1.14 – 1.42</b> )	< <b>0.0001</b>
<b>Generalized anxiety disorder</b>	1.10 (0.99 – 1.21)	<b>1.22</b> ( <b>1.10 – 1.35</b> )	<b>1.23</b> ( <b>1.11 – 1.36</b> )	< <b>0.0001</b>	1.06 (0.96 – 1.18)	<b>1.18</b> ( <b>1.07 – 1.31</b> )	<b>1.23</b> ( <b>1.11 – 1.36</b> )	<b>0.0002</b>	1.07 (0.97 – 1.19)	<b>1.20</b> ( <b>1.08 – 1.33</b> )	<b>1.23</b> ( <b>1.11 – 1.36</b> )	<b>0.0001</b>
<b>PTSD</b>	1.03 (0.93 – 1.13)	<b>1.19</b> ( <b>1.08 – 1.31</b> )	<b>1.35</b> ( <b>1.23 – 1.48</b> )	< <b>0.0001</b>	1.00 (0.90 – 1.11)	<b>1.15</b> ( <b>1.04 – 1.27</b> )	<b>1.35</b> ( <b>1.22 – 1.48</b> )	< <b>0.0001</b>	1.00 (0.91 – 1.11)	<b>1.16</b> ( <b>1.05 – 1.29</b> )	<b>1.34</b> ( <b>1.22 – 1.48</b> )	< <b>0.0001</b>
<b>Bipolar Disorder</b>	1.15 (0.98 – 1.36)	1.17 (0.99 – 1.38)	<b>1.25</b> ( <b>1.06 – 1.47</b> )	0.06	1.11 (0.94 – 1.31)	1.11 (0.94 – 1.31)	<b>1.21</b> ( <b>1.02 – 1.43</b> )	0.18	1.11 (0.94 – 1.31)	1.12 (0.95 – 1.32)	<b>1.20</b> ( <b>1.02 – 1.42</b> )	0.18
<b>Psychotic Experiences</b>	1.05 (0.95 – 1.17)	<b>1.17</b> ( <b>1.05 – 1.29</b> )	<b>1.21</b> ( <b>1.10 – 1.35</b> )	<b>0.0005</b>	1.03 (0.93 – 1.15)	<b>1.13</b> ( <b>1.02 – 1.26</b> )	<b>1.22</b> ( <b>1.10 – 1.35</b> )	<b>0.0004</b>	1.04 (0.93 – 1.15)	<b>1.14</b> ( <b>1.03 – 1.27</b> )	<b>1.21</b> ( <b>1.09 – 1.34</b> )	<b>0.0009</b>

Note: logistic regression was used for all outcomes and odds ratios (ORs) are presented with their 95% confidence intervals for each ascending night light quartile relative to the low light (Q1) referent. Model 1 is unadjusted. \*Model 2 adjusted for age, sex, ethnicity, and photoperiod as a measure of seasonality. <sup>†</sup>Model 3 is additionally adjusted for employment and physical activity. <sup>‡</sup>Likelihood ratio tests (LRT) were done as an omnibus test of significance for the night light factor. Bolded coefficients indicate significance at the .05 level.

**Table 3.** Associations between day light exposure and psychiatric outcomes

Day light	Model 1 OR (95% CI)				Model 2 aOR (95% CI)*				Model 3 aOR (95% CI)†			
	2 <sup>nd</sup> Quartile	3 <sup>rd</sup> Quartile	4 <sup>th</sup> Quartile	LRT <i>p</i> ‡	2 <sup>nd</sup> Quartile	3 <sup>rd</sup> Quartile	4 <sup>th</sup> Quartile	LRT <i>p</i> ‡	2 <sup>nd</sup> Quartile	3 <sup>rd</sup> Quartile	4 <sup>th</sup> Quartile	LRT <i>p</i> ‡
Major depressive disorder	<b>0.94</b> (0.90 – 1.00)	<b>0.91</b> (0.86 – 0.96)	<b>0.80</b> (0.76 – 0.85)	<0.0001	<b>0.91</b> (0.86 – 0.97)	<b>0.85</b> (0.80 – 0.90)	<b>0.75</b> (0.70 – 0.80)	<0.0001	<b>0.93</b> (0.88 – 0.99)	<b>0.88</b> (0.83 – 0.93)	<b>0.81</b> (0.76 – 0.87)	<0.0001
Self-harm	<b>0.87</b> (0.78 – 0.97)	<b>0.81</b> (0.73 – 0.90)	<b>0.77</b> (0.69 – 0.85)	<0.0001	<b>0.83</b> (0.75 – 0.93)	<b>0.76</b> (0.67 – 0.85)	<b>0.71</b> (0.63 – 0.81)	<0.0001	<b>0.85</b> (0.76 – 0.94)	<b>0.78</b> (0.70 – 0.88)	<b>0.76</b> (0.67 – 0.87)	0.0001
Generalized anxiety disorder	1.00 (0.90 – 1.10)	0.94 (0.85 – 1.03)	0.91 (0.82 – 1.00)	0.14	0.98 (0.89 – 1.09)	0.91 (0.82 – 1.02)	0.91 (0.81 – 1.03)	0.28	0.99 (0.90 – 1.10)	0.93 (0.84 – 1.04)	0.96 (0.85 – 1.09)	0.61
PTSD	0.94 (0.86 – 1.04)	0.92 (0.83 – 1.01)	<b>0.80</b> (0.73 – 0.89)	<b>0.0001</b>	0.91 (0.83 – 1.00)	<b>0.86</b> (0.77 – 0.95)	<b>0.75</b> (0.67 – 0.84)	<0.0001	0.93 (0.85 – 1.03)	<b>0.89</b> (0.81 – 0.99)	<b>0.82</b> (0.73 – 0.92)	<b>0.01</b>
Bipolar disorder	0.88 (0.75 – 1.04)	0.95 (0.81 – 1.12)	<b>0.81</b> (0.69 – 0.95)	0.06	0.86 (0.73 – 1.02)	0.94 (0.80 – 1.12)	<b>0.81</b> (0.67 – 0.99)	0.10	0.87 (0.74 – 1.03)	0.97 (0.81 – 1.15)	0.86 (0.70 – 1.05)	0.22
Psychotic Experiences	1.00 (0.91 – 1.10)	<b>0.88</b> (0.79 – 0.97)	<b>0.76</b> (0.69 – 0.85)	<0.0001	0.95 (0.86 – 1.06)	<b>0.79</b> (0.71 – 0.88)	<b>0.65</b> (0.57 – 0.74)	<0.0001	0.97 (0.88 – 1.07)	<b>0.81</b> (0.73 – 0.91)	<b>0.69</b> (0.61 – 0.79)	<0.0001

Note: logistic regression was used for all outcomes and odds ratios (ORs) are presented with their 95% confidence intervals for each ascending day light quartile relative to the low light (Q1) referent. Model 1 is unadjusted. \*Model 2 adjusted for age, sex, ethnicity, and photoperiod as a measure of seasonality. †Model 3 is additionally adjusted for employment and physical activity. ‡Likelihood ratio tests (LRT) were done as an omnibus test of significance for the day light factor. Bolded coefficients indicate significance at the .05 level.